Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

Introduction: Insulin-like growth factor signaling has been implicated in acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. This phase 1 trial (NCT02191891) investigated the combination of xentuzumab (an insulin-like growth factor-ligand neutralizing monoclonal antibody) and af...

Full description

Bibliographic Details
Main Authors: Keunchil Park, MD, PhD, Daniel Shao Weng Tan, BSc, M.B.B.S., MRCP, Wu-Chou Su, MD, Byoung Chul Cho, MD, PhD, Sang-We Kim, MD, PhD, Ki Hyeong Lee, MD, PhD, Chin-Chou Wang, MD, MS, Takashi Seto, MD, Dennis Chin-Lun Huang, MD, Helen Hayoun Jung, BS, RPh, Ming-Chi Hsu, PhD, Thomas Bogenrieder, MD, PhD, Chia-Chi Lin, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:JTO Clinical and Research Reports
Subjects:
Afatinib
EGFR tyrosine kinase inhibitor
IGF
NSCLC
Xentuzumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000655

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000655

Similar Items